甘氨双唑钠联合苦参注射液治疗食管癌术后复发患者的临床疗效分析

Clinical Effect Analysis of Sodium Glycididazole and Kushen Injection on the Treatment of Postoperative Recurrence of Patients with Esophageal Cancer

目的:探究甘氨双唑钠联合苦参注射液治疗食管癌术后复发患者的临床疗效和安全性。方法:选取经食管癌术后复发62例患者,随机分成对照组与联合组,每组31例。对照组给予甘氨双唑钠治疗,联合组在对照组基础上给予苦参注射液治疗。观察并比较两组患者治疗前后血清肿瘤标记物CEA、CA19-9、Cyfra21-1及SCC水平、1年和3年生存率、临床疗效及不良反应的发生情况。结果:与治疗前比较,两组患者治疗后血清CEA、CA19-9、Cyfra21-1及SCC水平均降低(P<0.05);且与对照组比较,联合组治疗后血清CEA、CA19-9、Cyfra21-1及SCC水平均较低(P<0.05),3年生存率较高(P<0.05),不良反应如恶心、呕吐、腹泻、肌酐升高、转氨酶升高及白细胞降低发生率更低(P<0.05)。结论:甘氨双唑钠联合苦参注射液可有效提高食管癌术后复发患者的临床疗效,延长患者生存时间,且安全性较高。

Objective： To investigate the clinical effect and safety of the sodium glycididazole with Kushen injection on the treatment of esophagectomy cancer. Methods： 62 patients with esophageal cancer recurrence were selected and randomly divided into the joint group and the control group with 31 cases in each group. Patients in the control group were treated with sodium glycididazole,and the patients in the joint group were treated with Kushen injection on the basis of the control group. Then the serum levels of CEA,CA19-9,SCC,and Cyfra21-1,and the survival rate,clinical efficacy and adverse reactions in the two groups were observed and compared before and after treatment. Results： Compared with before treatment,the serum levels of CEA,CA19-9,Cyfra21-1 and SCC decreased in the two groups after the treatment（P〈0.05）; Compared with the control group,the serum levels of CEA,CA19-9,Cyfra21-1and SCC in the joint group were lower after the treatment（P〈0.05）; The 3-year＇s survival rate in the joint group was higher than that of the control group（P〈0.05）; The adverse reactions in the joint group was lower than that of the control group（P〈0.05）. Conclusion： The clinical effect of the sodium and kushen injection on the treatment of postoperative recurrence of esophageal cancer patients can effectively improve the clinical curative effect and the survival time of patients with higher safety.